Leaders in Research Peptides

(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
(£) GBP (Default)
  • ($) USD
  • (€) EUR
  • ($) AUD
  • ($) CAD
  • ($) NZD
Highest Quality | For Research Use Only

Thymosin Alpha-1

Buy Thymosin Alpha-1 Peptide Estonia

Thymosin alpha-1 (Tα1) is a 28-amino acid peptide first isolated from calf thymuses. The peptide primarily functions as an immune system modulator, augmenting T-cell response, stimulating cytokine production, and enhancing the functional activities of natural killer cells. Consequently, Thymosin alpha-1 has found use in treating diseases associated with immune dysregulation.

In oncology, Thymosin alpha-1 has exhibited potential as an adjunctive therapy, bolstering the body’s immune response against tumor cells and thereby improving the effectiveness of conventional cancer treatments.

Showing all 4 results

Potential Benefits of Thymosin Alpha-1 Peptide

  • Treatment for Sepsis: Research suggests Thymosin Alpha-1 (Tα1) has shown potential benefits in the treatment of sepsis. Specifically, it has been suggested that certain patient groups may be more likely to benefit from Tα1 immunotherapy [1], [2] and [3].
  • Immune Modulation: According to research, Tα1 is noted for its immune-modulating properties. It has been found to have higher clinical benefit rates when used in conjunction with other treatments [4].
  • Dental Applications: In studies, Tα1 has demonstrated both short-term and long-term benefits in the reimplantation of avulsed teeth [5].
  • Broad Clinical Benefits: Since its first use in a clinical trial in 1985, a substantial amount of data has been produced supporting the potential clinical benefits of Tα1 [6].
  • Cancer Therapy: Tα1 has been reappraised for its use in cancer therapy, with studies suggesting a higher clinical benefit rate and a trend towards its use in conjunction with other treatments [7].
  • Treatment for Various Diseases: Research suggests the number of diseases that could potentially benefit from Tα1 treatment is growing, as it is a naturally occurring polypeptide [8].
  • Treatment for Chronic Hepatitis B: Studies indicate the combined use of Tα1 and entecavir has shown benefits in the treatment of chronic hepatitis B [9].
  • HIV-1 Treatment: Despite the consistent benefits for HIV-1 infected patients, more studies are needed concerning the use of Tα1 in HIV-1 infection [10].

References

[1] https://www.tandfonline.com/doi/ abs/10.1080/14712598.2018.1484104

[2] https://www.sciencedirect.com/science/ article/pii/S1201971214017500

[3] https://pubmed.ncbi.nlm.nih.gov/23327199/

[4] https://www.sciencedirect.com/science/ article/abs/pii/S0083672916300036

[5] https://pubmed.ncbi.nlm.nih.gov/18534287/

[6] https://nyaspubs.onlinelibrary.wiley.com/ doi/abs/10.1196/annals.1415.044

[7] https://www.frontiersin.org/journals/ oncology/articles/10.3389/fonc.2019.00873/full

[8] https://pubmed.ncbi.nlm.nih.gov/30063864/

[9] https://www.tandfonline.com/doi/ full/10.1517/14712598.2015.1007948

[10] https://pubmed.ncbi.nlm.nih.gov/28106477/

DISCLAIMER: We do not supply peptides to any individual under the age of 21. You must be a licensed and qualified healthcare practitioner. Our team of dedicated professionals are committed to providing an extensive range of products used ONLY in the process of laboratory research by responsible trained and professional individuals. All products listed on this website (https://estonia.direct-peptides.com) and provided through Direct Peptides are intended for laboratory research purposes only. The products listed on this website are NOT for human or animal consumption or ingestion of any kind.